Literature DB >> 23417276

Treatment of huntington disease.

Aleksandar Videnovic1.   

Abstract

OPINION STATEMENT: Many pharmacological agents have been utilized in the treatment of Huntington disease (HD). Several excellent reviews about the treatment of HD are available. Formal treatment guidelines are however lacking. This is mainly the result of limited evidence available in the literature. Further, available treatment studies are frequently hard to compare due to variable outcomes/instruments used, differences in the study population, and confounding effects of complex medication regimens. Generally speaking, the treatment paradigm for an HD patient will depend on the constellation of 3 main clinical domains affected in HD: motor, behavioral/psychiatric, and cognitive. Symptoms within each of these domains remain dynamic throughout the course of HD. It is therefore necessary to monitor patients clinically and adjust drugs accordingly as the disease progresses. The most commonly used chorea drugs are antipsychotics and tetrabenazine (TBZ). Antipsychotic drugs are preferred in patients with coexistent psychiatric/behavioral comorbidities as well as in the presence of depression. Amantadine may be considered in the treatment of chorea, but data supporting its effectiveness remain conflicting. Selective serotonin reuptake inhibitors (SSRIs) are the treatment of choice for irritability and obsessive-compulsive behaviors associated with HD. Antipsychotic agents and antiepileptic mood stabilizers may be used as add-on therapies. There is very limited evidence for the treatment of cognitive impairment associated with HD. Each drug used in treatment of HD has a potential for causing significant side effects. It is, therefore, critical to assess the risk-benefit ratio on an individual basis, and carefully monitor patients throughout the course of treatment. Non-pharmacological and surgical treatment strategies for HD have not been systematically explored. Despite the lack of evidence, behavioral interventions, as well as physical, occupational, and speech therapies may provide additional benefits to a wide spectrum of disabilities associated with HD.

Entities:  

Year:  2013        PMID: 23417276      PMCID: PMC3677041          DOI: 10.1007/s11940-013-0219-8

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  64 in total

1.  Riluzole and olanzapine in Huntington's disease.

Authors:  Raphael M Bonelli; G Niederwieser; J Diez; P Költringer
Journal:  Eur J Neurol       Date:  2002-03       Impact factor: 6.089

2.  Quetiapine in Huntington's disease: a first case report.

Authors:  Raphael M Bonelli; Gerald Niederwieser
Journal:  J Neurol       Date:  2002-08       Impact factor: 4.849

3.  [Olanzapine improves chorea in patients with Huntington's disease].

Authors:  F J Jiménez-Jiménez; M de Toledo; I Puertas; M Barón; M Zurdo; B Barcenilla
Journal:  Rev Neurol       Date:  2002 Sep 16-30       Impact factor: 0.870

4.  Clozapine versus placebo in Huntington's disease: a double blind randomised comparative study.

Authors:  J P van Vugt; S Siesling; M Vergeer; E A van der Velde; R A Roos
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-07       Impact factor: 10.154

5.  IV amantadine improves chorea in Huntington's disease: an acute randomized, controlled study.

Authors:  J M Heckmann; P Legg; D Sklar; J Fine; A Bryer; B Kies
Journal:  Neurology       Date:  2004-08-10       Impact factor: 9.910

6.  A controlled trial of fluoxetine in nondepressed patients with Huntington's disease.

Authors:  P G Como; A J Rubin; C F O'Brien; K Lawler; C Hickey; A E Rubin; R Henderson; M P McDermott; M McDermott; K Steinberg; I Shoulson
Journal:  Mov Disord       Date:  1997-05       Impact factor: 10.338

7.  Functional and motor response to low dose olanzapine in Huntington's disease: case report.

Authors:  Jerson Laks; Marlos Rocha; Claudia Capitão; Romeu Côrtes Domingues; Giovanna Ladeia; Maurício Lima; Eliasz Engelhardt
Journal:  Arq Neuropsiquiatr       Date:  2004-12-15       Impact factor: 1.420

8.  Ziprasidone in Huntington's disease: the first case reports.

Authors:  Raphael M Bonelli; Brigitte M Mayr; Gerald Niederwieser; Franz Reisecker; Hans-Peter Kapfhammer
Journal:  J Psychopharmacol       Date:  2003-12       Impact factor: 4.153

9.  IV amantadine improves chorea in Huntington's disease: an acute randomized, controlled study.

Authors:  C Lucetti; P Del Dotto; G Gambaccini; G Dell' Agnello; S Bernardini; G Rossi; L Murri; U Bonuccelli
Journal:  Neurology       Date:  2003-06-24       Impact factor: 9.910

10.  Randomized controlled trial of ethyl-eicosapentaenoic acid in Huntington disease: the TREND-HD study.

Authors: 
Journal:  Arch Neurol       Date:  2008-12
View more
  13 in total

Review 1.  Neurotheranostics as personalized medicines.

Authors:  Bhavesh D Kevadiya; Brendan M Ottemann; Midhun Ben Thomas; Insiya Mukadam; Saumya Nigam; JoEllyn McMillan; Santhi Gorantla; Tatiana K Bronich; Benson Edagwa; Howard E Gendelman
Journal:  Adv Drug Deliv Rev       Date:  2018-10-26       Impact factor: 15.470

2.  Rutin and Selenium Co-administration Reverse 3-Nitropropionic Acid-Induced Neurochemical and Molecular Impairments in a Mouse Model of Huntington's Disease.

Authors:  Mohamed S Abdelfattah; Sherif E A Badr; Sally A Lotfy; Gouda H Attia; Ahmed M Aref; Ahmed E Abdel Moneim; Rami B Kassab
Journal:  Neurotox Res       Date:  2019-07-22       Impact factor: 3.911

Review 3.  Current and Possible Future Therapeutic Options for Huntington's Disease.

Authors:  Mackenzie W Ferguson; Connor J Kennedy; Thulani H Palpagama; Henry J Waldvogel; Richard L M Faull; Andrea Kwakowsky
Journal:  J Cent Nerv Syst Dis       Date:  2022-05-21

4.  Medication Use in Early-HD Participants in Track-HD: an Investigation of its Effects on Clinical Performance.

Authors:  Ruth Keogh; Chris Frost; Gail Owen; Rhian M Daniel; Doug R Langbehn; Blair Leavitt; Alexandra Durr; Raymund A C Roos; G Bernhard Landwehrmeyer; Ralf Reilmann; Beth Borowsky; Julie Stout; David Craufurd; Sarah J Tabrizi
Journal:  PLoS Curr       Date:  2016-01-11

5.  Speech and language therapy for management of chronic cough.

Authors:  Claire Slinger; Syed B Mehdi; Stephen J Milan; Steven Dodd; Jessica Matthews; Aashish Vyas; Paul A Marsden
Journal:  Cochrane Database Syst Rev       Date:  2019-07-23

6.  State-of-the-art pharmacological approaches to reduce chorea in Huntington's disease.

Authors:  Jessie S Gibson; Daniel O Claassen
Journal:  Expert Opin Pharmacother       Date:  2021-02-08       Impact factor: 4.103

7.  Allele-specific suppression of mutant huntingtin using antisense oligonucleotides: providing a therapeutic option for all Huntington disease patients.

Authors:  Niels H Skotte; Amber L Southwell; Michael E Østergaard; Jeffrey B Carroll; Simon C Warby; Crystal N Doty; Eugenia Petoukhov; Kuljeet Vaid; Holly Kordasiewicz; Andrew T Watt; Susan M Freier; Gene Hung; Punit P Seth; C Frank Bennett; Eric E Swayze; Michael R Hayden
Journal:  PLoS One       Date:  2014-09-10       Impact factor: 3.240

Review 8.  Compounds with anti-influenza activity: present and future of strategies for the optimal treatment and management of influenza. Part I: Influenza life-cycle and currently available drugs.

Authors:  R Gasparini; D Amicizia; P L Lai; N L Bragazzi; D Panatto
Journal:  J Prev Med Hyg       Date:  2014-09

Review 9.  Current Pharmacological Approaches to Reduce Chorea in Huntington's Disease.

Authors:  Emma M Coppen; Raymund A C Roos
Journal:  Drugs       Date:  2017-01       Impact factor: 9.546

10.  Genomic Analysis Reveals Disruption of Striatal Neuronal Development and Therapeutic Targets in Human Huntington's Disease Neural Stem Cells.

Authors:  Karen L Ring; Mahru C An; Ningzhe Zhang; Robert N O'Brien; Eliana Marisa Ramos; Fuying Gao; Robert Atwood; Barbara J Bailus; Simon Melov; Sean D Mooney; Giovanni Coppola; Lisa M Ellerby
Journal:  Stem Cell Reports       Date:  2015-12-08       Impact factor: 7.765

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.